The global colorectal cancer diagnostics and therapeutics market is witnessing steady growth due to the rising prevalence of colorectal cancer, increasing awareness about early screening, and advancements in precision medicine. Growing adoption of non-invasive diagnostic technologies such as liquid biopsy, stool-based DNA tests, and molecular diagnostics is further accelerating market expansion. In therapeutics, the emergence of targeted therapies and immunotherapies is improving treatment outcomes and driving demand worldwide.

New York, USA, May 13, 2026 (GLOBE NEWSWIRE) -- Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

DelveInsight’s Colorectal Cancer Diagnostics and Therapeutics Market Insights report provides the current and forecast market analysis, individual leading colorectal cancer diagnostics and therapeutics companies’ market shares, challenges, colorectal cancer diagnostics and therapeutics market drivers, barriers, trends, and key colorectal cancer diagnostics and therapeutics companies in the market.

Colorectal Cancer Diagnostics and Therapeutics Market Summary

2025 Colorectal Cancer Diagnostics and Therapeutics Market Size: USD 35 Billion
2034 Projected Colorectal Cancer Diagnostics and Therapeutics Market Size: USD 73 Billion
Colorectal Cancer Diagnostics and Therapeutics Market Growth Rate (2026-2034): ~9%
Largest Colorectal Cancer Diagnostics and Therapeutics Market: North America
Largest Modality Segment: Diagnostic Category
Key Companies in the Colorectal Cancer Diagnostics and Therapeutics Market: Exact Sciences Corporation, Guardant Health, F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Epigenomics AG, Eiken Chemical Co., Ltd., Clinical Genomics Technologies, VolitionRx Ltd., Siemens Healthineers, Olympus Corporation, Fujifilm Holdings Corporation, Medtronic plc, Merck & Co., Inc., Bristol-Myers Squibb, Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Bayer AG, Johnson & Johnson, Taiho Pharmaceutical, and others

To read more about the latest highlights related to the colorectal cancer diagnostics and therapeutics market, get a snapshot of the key highlights @ https://www.delveinsight.com/sample-request/colorectal-cancer-diagnostics-and-therapeutics-market

Key Factors Contributing to the Rise in Growth of the Colorectal Cancer Diagnostics and Therapeutics Market

Rising Incidence of Colorectal Cancer: The growing global burden of colorectal cancer is one of the primary drivers of market growth. Factors such as aging populations, sedentary lifestyles, obesity, smoking, unhealthy dietary habits, and increasing alcohol consumption have contributed to the rising number of colorectal cancer cases across both developed and emerging economies.
Growing Emphasis on Early Detection and Screening: Governments and healthcare organizations are increasingly promoting colorectal cancer screening programs to improve early diagnosis and survival outcomes. Expanded screening guidelines, awareness campaigns, and preventive healthcare initiatives are encouraging regular screening through colonoscopy, stool-based tests, and blood-based assays.
Advancements in Diagnostic Technologies: Rapid technological innovations are transforming colorectal cancer diagnostics. The development of non-invasive and highly sensitive screening methods such as liquid biopsy, stool DNA testing, circulating tumor DNA (ctDNA) analysis, next-generation sequencing (NGS), molecular diagnostics, and AI-assisted colonoscopy has improved diagnostic accuracy and patient compliance.
Increasing Adoption of Precision Medicine and Targeted Therapies: The shift toward personalized medicine is significantly driving the therapeutics segment of the market. Biomarker-guided therapies, immunotherapies, and targeted treatments focused on KRAS, EGFR, HER2, and MSI-H/dMMR mutations are improving treatment efficacy and patient outcomes.
Rising Demand for Minimally Invasive Diagnostic Solutions: Patients and healthcare providers are increasingly preferring minimally invasive diagnostic approaches due to greater convenience, reduced discomfort, and improved adherence to screening programs.
Expanding Healthcare Infrastructure and Healthcare Spending: Growing investments in healthcare infrastructure, especially in emerging economies such as China and India, are improving access to cancer screening, diagnostics, and treatment services.
Regulatory Approvals and Product Launches: Continuous regulatory approvals for innovative diagnostics and therapies are accelerating market growth. The introduction of advanced screening tests, AI-powered diagnostic tools, and novel immunotherapy combinations is expanding the available treatment landscape and increasing competition among key market players.
Increasing Integration of AI and Digital Health Technologies: Artificial intelligence and digital pathology solutions are enhancing the efficiency and accuracy of colorectal cancer detection. AI-assisted colonoscopy systems improve adenoma detection rates, while digital imaging and data analytics support faster clinical decision-making and workflow optimization in healthcare settings.

Get a sneak peek at the colorectal cancer diagnostics and therapeutics market dynamics @ Colorectal Cancer Diagnostics and Therapeutics Market Trends

Regional Colorectal Cancer Diagnostics and Therapeutics Market Insights

North America

Among all regions, North America held the largest share of the colorectal cancer diagnostics and therapeutics market in 2025, contributing approximately 41% of the total market.
The region’s leadership is primarily driven by the rising incidence of colorectal cancer, advanced healthcare systems, and the strong presence of major pharmaceutical and diagnostic players.
Growth is further supported by the extensive use of innovative screening and treatment approaches, including molecular diagnostics and targeted therapies, as well as supportive reimbursement frameworks.
Moreover, growing public awareness campaigns and government-led initiatives focused on early cancer detection are expected to continue fueling market expansion across North America.

Europe

The Europe colorectal cancer diagnostics and therapeutics market is experiencing robust growth, driven by the increasing prevalence of the disease, a growing elderly population, and ongoing improvements in healthcare infrastructure and oncology-focused research.
The region benefits from a highly developed healthcare ecosystem with broad access to screening methods such as colonoscopy and molecular diagnostic technologies, enabling earlier detection and more effective intervention.
Rising utilization of targeted treatments, immunotherapies, and precision medicine is further enhancing clinical outcomes while boosting demand for sophisticated diagnostic and therapeutic solutions.
In addition, the strong presence of major pharmaceutical companies and extensive collaborative clinical research networks across European nations continues to support innovation and rapid adoption of emerging technologies.
Government-backed awareness campaigns and organized cancer screening programs are also playing a vital role in promoting early diagnosis and treatment.
Countries including Germany, France, and the UK are contributing significantly to market growth through increased oncology investments and evolving treatment approaches.

Asia-Pacific

The Asia-Pacific region is becoming a significant contributor to the growth of the colorectal cancer diagnostics and therapeutics market, fueled by the rising prevalence of the disease, advancements in healthcare infrastructure, and increasing awareness regarding the importance of early detection.
Nations including China, India, and Japan are experiencing a consistent increase in colorectal cancer incidence, primarily due to aging demographics, rapid urbanization, and evolving lifestyle patterns.
Simultaneously, regional governments are strengthening cancer screening initiatives and increasing investments in healthcare systems, thereby improving access to advanced diagnostic tools such as colonoscopy, imaging technologies, and molecular diagnostics.
Moreover, the growing use of targeted treatments, immunotherapies, and precision medicine is improving clinical outcomes and accelerating demand for innovative therapeutic solutions.
Factors such as a large patient population, expanding medical tourism industry, and increasing healthcare spending are also contributing to market growth, positioning APAC as the fastest-expanding regional market worldwide.

To know more about why North America is leading the market growth in the colorectal cancer diagnostics and therapeutics market, get a snapshot of the Colorectal Cancer Diagnostics and Therapeutics Market Share

Recent Developmental Activities in the Colorectal Cancer Diagnostics and Therapeutics Market

In September 2025, the EU certified the MMR IHC Panel pharmDx as a companion diagnostic to identify patients eligible for immunotherapy combinations such as nivolumab and ipilimumab, enhancing personalized treatment selection.
In August 2025, companion diagnostics such as MMR IHC panels received FDA approvals, enabling better identification of patients eligible for immunotherapies.
In April, 2025, the U.S. FDA approved the combination of Nivolumab (Opdivo) and Ipilimumab (Yervoy) as a first-line treatment for unresectable or metastatic MSI-H/dMMR colorectal cancer, marking a significant advancement in immunotherapy-based treatment options.
In June 2025, Sakar Healthcare received its second European Union (EU) marketing authorization for an oncology injection product, specifically targeting colorectal cancer treatment.

What are Colorectal Cancer Diagnostics and Therapeutics?

Colorectal cancer diagnostics and therapeutics encompass the range of medical technologies, tests, and treatment approaches used to detect, diagnose, monitor, and manage colorectal cancer, which affects the colon or rectum. Diagnostics include screening and detection methods such as fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), colonoscopy, sigmoidoscopy, biopsy, molecular diagnostics, and imaging techniques like CT, MRI, and PET scans that help identify tumors and determine disease stage. Advances in biomarker testing and genetic profiling are also enabling earlier detection and personalized treatment planning. Therapeutics involve a combination of surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and emerging precision medicine approaches aimed at improving survival outcomes and reducing disease recurrence. The growing focus on early screening programs, minimally invasive procedures, and novel targeted treatments is significantly transforming the colorectal cancer care landscape worldwide.

Colorectal Cancer Diagnostics and Therapeutics Market Report Metrics	Details
Coverage	Global
Study Period	2023–2034
Colorectal Cancer Diagnostics and Therapeutics Market CAGR	~9%
Colorectal Cancer Diagnostics and Therapeutics Market Size by 2034	USD 73 Billion
Key Colorectal Cancer Diagnostics and Therapeutics Companies	Exact Sciences Corporation, Guardant Health, F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Epigenomics AG, Eiken Chemical Co., Ltd., Clinical Genomics Technologies, VolitionRx Ltd., Siemens Healthineers, Olympus Corporation, Fujifilm Holdings Corporation, Medtronic plc, Merck & Co., Inc., Bristol-Myers Squibb, Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Bayer AG, Johnson & Johnson, Taiho Pharmaceutical, and others

Colorectal Cancer Diagnostics and Therapeutics Market Assessment

Colorectal Cancer Diagnostics and Therapeutics Market Segmentation
- Colorectal Cancer Diagnostics and Therapeutics Market Segmentation By Modality: Diagnostics {Blood Test, Stool Test, Imaging Test, Biopsy, and Others} and Therapeutics {Chemotherapy, Immunotherapy, Targeted Therapy, and Others}
- Colorectal Cancer Diagnostics and Therapeutics Market Segmentation By End User: Hospitals, Diagnostic Laboratories, Cancer Research Institutes, and Others
- Colorectal Cancer Diagnostics and Therapeutics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the colorectal cancer diagnostics and therapeutics market are set to emerge as the trendsetter explore @ Colorectal Cancer Diagnostics and Therapeutics Market Analysis

Table of Contents

1	Colorectal Cancer Diagnostics and Therapeutics Market Report Introduction
2	Colorectal Cancer Diagnostics and Therapeutics Market Executive Summary
3	Colorectal Cancer Diagnostics and Therapeutics Market Key Factors Analysis
4	Impact Analysis
5	Regulatory Analysis
6	Colorectal Cancer Diagnostics and Therapeutics Market Porter’s Five Forces Analysis
7	Colorectal Cancer Diagnostics and Therapeutics Market Assessment
8	Competitive Landscape
9	Startup Funding & Investment Trends
10	Colorectal Cancer Diagnostics and Therapeutics Market Company and Product Profiles
11	KOL Views
12	Project Approach
13	About DelveInsight
14	Disclaimer & Contact Us

Interested in knowing the colorectal cancer diagnostics and therapeutics market share by 2034? Click to get a snapshot of the Colorectal Cancer Diagnostics and Therapeutics Market Size

Related Reports

Colorectal Cancer Market

Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CRC companies, including Shanghai Henlius Biotech, Agenus, Tizona Therapeutics, Surgimab, Novartis, Bexion Pharmaceuticals, Syndax Pharmaceuticals, Exelixis, AbbVie, Tyligand Pharmaceuticals, Bristol Myers Squibb, Eisai, Bold Therapeutics, Takeda, Merck Sharp & Dohme, and others.

Colorectal Cancer Clinical Trial Analysis

Colorectal Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CRC companies, including Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.

AI in Cancer Diagnostics Market

AI in Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key AI in cancer diagnostics companies, including iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and others.

Molecular Diagnostics Market

Molecular Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key molecular diagnostics companies, including Hoffmann-La Roche Ltd., Hologic, Inc., bioMérieux SA, Abbott, QIAGEN, BD, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Myriad Genetics, Inc., Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., MDxHealth, Genetic Signatures, Biocartis, Exact Sciences Corporation, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and others.

Companion Diagnostics Market

Companion Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key companion diagnostics companies, including Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott Laboratories, QIAGEN, BIOMÉRIEUX, Guardant Health Inc., Illumina, Inc., Pillar Biosciences, Inc., Leica Biosystems, Thermo Fisher Scientific Inc., Almac Group, NeoGenomics Laboratories, Invitae Corporation, 3D Medicines Corporation, ASURAGEN, INC. (Biotechne), Invivoscribe, Inc., Amoy Diagnostics Co., Ltd., Laboratory Corporation of America® Holdings, SAGA Diagnostics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679